Author

admin

Browsing

Senate Minority Leader Chuck Schumer, D-N.Y., is threatening to sue the Trump administration if they don’t release the Epstein files.

Late last month, Schumer and every Senate Democrat on the Senate Homeland Security and Governmental Affairs Committee invoked an arcane, nearly century-old law to compel the Trump administration to release information on Jeffrey Epstein.

The move came as Epstein drama had already paralyzed the House, and as Democrats in the upper chamber began to ramp up their messaging against President Donald Trump for his handling of the issue.

And Friday was the deadline for the Justice Department and White House to comply, and so far, the documents have not been given to Schumer and Senate Democrats.

‘They’re now breaking the law to hide the files,’ Schumer said on X. ‘[Senate Majority Leader John Thune] must appoint a lawyer to defend the Senate in Court and get the files.’

‘If he chooses complicity — we’ll take them to court ourselves.’

The Justice Department declined to comment on the matter. Fox News Digital reached out to the White House and Thune’s office for comment.

However, a senior GOP aide noted to Fox News Digital that it’s not entirely up to the South Dakota Republican to appoint legal counsel to represent the Senate. Instead, that falls onto the Senate Joint Leadership Group, which includes Thune, Sen. Chuck Grassley, R-Iowa, and the president pro-tempore of the Senate, Schumer, and the chairs and ranking members of the Senate Judiciary and, in this case, the Homeland Security committees.

That committee would have to approve legal counsel on a two-thirds vote. Or, the Senate could vote on a resolution to grant legal counsel, which also requires two-thirds of lawmakers to advance. 

Last month, Democrats invoked the ‘rule of five,’ a 1928 law that requires government agencies to hand over information if any five lawmakers on a Senate or House committee with jurisdiction over the information make a request. Typically, it’s viewed as a tool of the minority party to exert oversight powers.

In a letter sent to the White House and the DOJ, Schumer and Democrats on the Senate Homeland Security panel charged that it was ‘essential that the Trump Administration provide full transparency,’ in releasing the files related to the late pedophile.

‘We call on you to fulfill those promises of transparency,’ they wrote.

Democrats’ request included all documents, files, evidence and other materials that DOJ had related to the case of U.S. v. Jeffrey Epstein, along with any records related to Epstein and his clients.

However, whether the law is enforceable in court remains to be seen, given that it has seldom been used since its inception.

The last attempt came in 2017, when Democrats tried to force the release of documents surrounding the lease of the Old Post Office building in the District, which became one of Trump’s hotels.  

This post appeared first on FOX NEWS

Sen. Josh Hawley, R-Mo., is launching an investigation into Meta after reports found that the company green-lit internal rules that allowed AI chatbots to have ‘romantic’ and ‘sensual’ exchanges with children. 

Hawley, who chairs the Senate Judiciary Subcommittee on Crime and Counterterrorism, wrote in a letter to Meta CEO Mark Zuckerberg that his committee will dive into whether Meta’s generative-Al products enabled exploitation, deception or other criminal harms to children. Further, the probe will look at whether Meta misled the public or regulators about its safeguards on AI.

‘I already have an ongoing investigation into Meta’s stunning complicity with China — but Zuckerberg siccing his company’s AI chatbots on our kids called for another one,’ Hawley told Fox News Digital. ‘Big Tech will know no boundaries until Congress holds social media outlets accountable. And I hope my colleagues on both sides of the aisle can agree that exploiting children’s innocence is a new low.’

Hawley demanded that the company must produce a trove of materials related to internal policies on the chatbots, communications and more to the panel by Sept. 19.

His announcement on Friday comes after Reuters first reported that Meta, which is the parent company to Facebook, had given the go-ahead to policies on chatbot behavior that allowed the AI to ‘engage a child in conversations that are romantic or sensual.’

Hawley noted that Meta acknowledged the reports and charged that the company ‘made retractions only after this alarming content came to light’ in his letter to Zuckerberg.

‘To take but one example, your internal rules purportedly permit an Al chatbot to comment that an 8-year-old’s body is ‘a work of art’ of which ’every inch… is a masterpiece — a treasure I cherish deeply,’’ he wrote.

‘Similar conduct outlined in these reports is reprehensible and outrageous and demonstrates a cavalier attitude when it comes to the real risks that generative Al presents to youth development absent strong guardrails,’ Hawley continued. ‘Parents deserve the truth, and kids deserve protection.’

A spokesperson for Meta confirmed to Fox News Digital that the document reviewed by Reuters was real but countered that ‘it does not accurately reflect our policies.’ 

‘We have clear policies on what kind of responses AI characters can offer, and those policies prohibit content that sexualizes children and sexualized role play between adults and minors,’ the spokesperson said. ‘Separate from the policies, there are hundreds of examples, notes, and annotations that reflect teams grappling with different hypothetical scenarios. The examples and notes in question were and are erroneous and inconsistent with our policies, and have been removed.’

The document in question, known as the ‘GenAI: Content Risk Standards,’ included over 200 pages of rules that outlined what workers at Meta should consider as acceptable behavior when building and training chatbots and other AI-generative products for the company.

Hawley demanded that the company produce all iterations of the GenAI: Content Risk Standards, all products that fall under the scope of the guidelines, how the guidelines are enforced, risk reviews and incident reports that reference minors, sexual or romantic role-play, in-person meetups, medical advice, self-harm, or criminal exploitation, communications with regulators and a paper trail on who decided and when to revise the standards and what changes were actually made. 

This post appeared first on FOX NEWS

Congressional Democrats remained skeptical that any progress toward an end to the war in Ukraine would be made ahead of the meeting between President Donald Trump and Russian President Vladimir Putin.

The high-stakes meeting in Anchorage, Alaska, comes as lawmakers have grown anxious to see an end to the conflict between Russia and Ukraine, and with many ready to slap a bone-breaking sanctions package on Moscow and its allies unless Putin relents.

But Democrats are not so sure that Trump will yield results in his closed-door meeting with Putin, the first between U.S. and Russian leaders since the invasion of Ukraine in 2022.

‘I fear this meeting could once again end with America ceding ground to an autocrat who has spent his career undermining democratic values,’ Sen. Mark Warner, D-Va., and the top Democrat on the Senate Intel Committee, said.

He warned that there could be no concessions without Ukraine’s involvement, Russia’s withdrawal from Ukrainian territory and ‘enforceable guarantees’ for Ukraine’s security.

‘Anything less would be an invitation for further aggression from Moscow and every autocrat watching to see if the United States still has the backbone to defend the principles that have kept Americans safe since the Second World War,’ he said.  

House Minority Leader Hakeem Jeffries, D-N.Y., accused Trump of previously ‘playing footsie’ with Putin, but noted that it appeared that the president’s disposition toward his Russian counterpart had shifted.

He added that last year, House Democrats and Republicans worked together to pass another military aid package for Ukraine, and likened it to a ‘Churchill or Chamberlain moment.’

‘We are either going to appease the dictator or we’re going to aggressively oppose the dictator,’ Jeffries said. ‘And as we saw with Chamberlain, appeasing the dictator never works.’

Trump himself sought to set expectations for the summit, telling Fox News Radio earlier this week that there would be a 25% chance that the meeting would end in failure.

And aboard Air Force One, Trump told reporters that he wanted to ‘see a ceasefire rapidly.’

‘I don’t know if it’s going to be today, but I’m not going to be happy if it’s not today,’ he said. ‘Everyone said it can’t be today, but I’m just saying I want the killing to stop.’

The Trump administration has threatened to slap secondary tariffs on India, a major buyer of Russian oil, if the meeting did not go well. That comes after Trump gave Putin a 50-day deadline to reach a ceasefire agreement, which the president recently shortened to ’10 or 12′ days.

Sen. Jeanne Shaheen, the top Democrat on the Senate Foreign Intelligence Committee, told reporters that ‘people have been willing to give the White House and the president the benefit of the doubt.’

‘But if he doesn’t produce anything at this summit, after drawing red line after red line … there will be growing concern and a growing pressure to try and get something done,’ the New Hampshire Democrat said.

One area where many lawmakers in the upper chamber agree is the necessity for a sanctions package against Russia. Currently, Sens. Lindsey Graham, R-S.C., and Richard Blumenthal, D-Conn., have a bill in the works that would slap up to 500% tariffs on countries buying energy products from Moscow.

Blumenthal told MSNBC earlier this week if Trump stood firm and insisted on a ceasefire, Putin come to the table with European leaders and secure security guarantees ‘he has the makings of a potential agreement that could win him the Nobel Peace Prize.’

‘But my fear is that he will be the mercurial Donald Trump who allowed the deadline for sanctions to pass last Friday without any imposition of new levies on Russia, and that he will fail to adhere to those principles adopted yesterday by the European countries in their meeting,’ he said. 

This post appeared first on FOX NEWS

As President Donald Trump greeted Russian President Vladimir Putin on the tarmac at Joint Base Elmendorf-Richardson, a B-2 stealth bomber soared overhead, flanked by four F-35 jets. 

Putin looked up at the sky as the planes buzzed overhead while he walked alongside Trump, and then made a comment to the U.S. president. 

The display was as much a symbol as it was a show of force—a pointed reminder of America’s military reach at the very moment the two leaders prepared to discuss the future of global security.

The dramatic arrival underscored the high-stakes nature of the Alaska summit, the first face-to-face meeting between Trump and Putin since Trump’s return to the White House earlier this year. Joint Base Elmendorf-Richardson, situated just outside Anchorage, was chosen for its robust security, strategic location, and symbolic position—physically closer to Russia than Washington, D.C., yet firmly on American soil.

Onlookers in Anchorage and across social media quickly seized on the moment. Many called it an ‘insane flex,’ noting the B-2 bomber’s recent combat history.

Only two months ago, the stealth aircraft played a central role in U.S. and Israeli strikes on Iranian nuclear facilities, dropping bunker-buster bombs in a move that drew both praise and condemnation on the world stage.

The B-2 Spirit, built by Northrop Grumman, is one of the most advanced aircraft ever created—capable of penetrating dense air defenses and striking targets anywhere in the world without refueling. Its distinctive flying-wing design and radar-absorbent coating make it nearly invisible to enemy radar. 

With a range of over 6,000 nautical miles and the ability to carry both conventional and nuclear weapons, the B-2 serves as a critical component of America’s nuclear triad. Only 21 were ever built, and fewer than 20 remain in service, making any public appearance a rare and deliberate statement.

‘Absolutely incredible,’ wrote one X user. Another added, ‘Putin now knows what will be greeting him if he were to ever cross that line that should never be crossed.’

After the brief tarmac ceremony, Putin entered ‘The Beast’ alongside Trump. The heavily armored presidential limousine rolled past a row of American fighter jets lined up in silent formation, their presence another visual reminder of the stakes surrounding the talks.

The two leaders traveled to a secure meeting hall on the base, beginning discussions at about 3:30 p.m. Eastern Time. Trump has said he plans to ‘set the table’ during the meeting for a future summit that includes Ukrainian President Volodymyr Zelenskyy. But still, he told Fox News’ Bret Baier he ‘won’t be happy’ if Putin does not agree to a ceasefire in Ukraine. 

This post appeared first on FOX NEWS

Ukrainian President Volodymyr Zelenskyy said on Saturday he will travel to Washington, D.C. on Monday to meet with President Donald Trump.

Zelenskyy’s announcement comes a day after Trump met with Russian President Vladimir Putin in Alaska on Friday to negotiate an end to the war in Ukraine.

‘On Monday, I will meet with President Trump in Washington, D.C., to discuss all of the details regarding ending the killing and the war. I am grateful for the invitation,’ Zelenskyy wrote on X.

This is a breaking news story. Check back for updates.

This post appeared first on FOX NEWS

Here’s a quick recap of the crypto landscape for Wednesday (August 15) as of 9:00 a.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$117,981, following a volatile 24 hours. Its lowest valuation of the day was US$117,547, while its highest so far was US$119,315.

Bitcoin price performance, August 15, 2025.

Chart via TradingView

Bitcoin surged to a new all-time high of $124,533 on Thursday (August 14), driven by expectations of Federal Reserve rate cuts and increased institutional interest. However, the rally was short-lived, as the price fell as low as $117,263 early Friday.

The decline was attributed to a higher-than-expected US Producer Price Index (PPI) for July, which dampened investor optimism about imminent interest rate reductions. Additionally, comments from US Treasury Secretary Scott Bessent revealed that the US holds fewer Bitcoin reserves than previously thought, further unsettling the market.

Meanwhile, Ethereum’s (ETH) weekend rally briefly has worn off, currently down by 3 percent to US$4,556.55. The cryptocurrency’s lowest valuation on Friday was US$4,462.52, and its highest was US$4,690.57.

Altcoin price update

  • Solana (SOL) was priced at US$189.85, down by 4.3 percent over 24 hours. Its highest valuation of the day was at US$198.27, while its lowest valuation was US$188.80.
  • XRP was trading for US$3.08, down 1.7 percent in the past 24 hours. Its highest valuation of the day was at US$3.14, while its lowest was US$3.04.
  • Sui (SUI) was trading at US$3.75, down by 2.53 percent over the past 24 hours. Its highest valuation of the day was at US$3.78, while its lowest was US$3.68.
  • Cardano (ADA) was trading at US$0.9485, up by 1.7 percent over 24 hours. Its highest valuation of the day was at US$0.9605, while its lowest was US$0.9362.

Today’s crypto news to know

Ethereum ETFs cruise past Bitcoin, totals nearly US$3 billion in a week

Ethereum-focused exchange-traded funds have seen an unprecedented surge in investor demand, attracting almost US$3 billion in net inflows over the past week.

According to SoSoValue data, this growth is more than five times the US$562 million that flowed into Bitcoin ETFs during the same period. The spike coincides with a rapid increase in Ethereum holdings by crypto treasury firms, which climbed from US$600 million to US$11 billion in just six weeks.

ETF Store president Nate Geraci noted that three of the four largest single-day inflows for Ethereum ETFs since their inception occurred this week alone.

ETH prices have rallied nearly 19 percent over the past seven days, coming within reach of their 2021 all-time high of US$4,878.

The inflows also follow recent SEC approval of in-kind creations and redemptions for spot Bitcoin and Ethereum ETFs, a change that makes the funds more cost-efficient and attractive to institutional investors.

Michael Saylor bets on US$100 billion ‘bitcoin credit’

Michael Saylor, executive chairman of Strategy (NASDAQ:MSTR) (formerly MicroStrategy), is pursuing a high-risk plan to finance further Bitcoin purchases through perpetual preferred stock offerings.

The new securities—nicknamed “Stretch”—do not mature, lack voting rights, and can skip dividends under certain conditions, giving the issuer flexibility while raising investor concerns about risk.

This marks a departure from the company’s earlier reliance on common stock sales and convertible bonds to fund what is now a US$75 billion Bitcoin treasury. Saylor aims to retire billions in outstanding debt and replace it with preferred equity, which he says could theoretically scale to US$100 billion or more in capital raised.

The model hinges on investor appetite for yield backed indirectly by Bitcoin’s performance, while avoiding the dilution impact of issuing more common stock.

Hong Kong SFC rolls out stricter rules for licensed Crypto platforms

Hong Kong’s Securities and Futures Commission (SFC) has introduced new custody rules for licensed virtual asset trading platforms, setting stricter benchmarks for how client assets must be stored and secured.

The updated framework includes specific requirements for cold wallet usage, senior management accountability, and real-time cyber-threat monitoring, alongside rules for using third-party wallet providers.

These measures follow an SFC review earlier this year that identified security and operational gaps among some licensed exchanges. The regulator says the changes are part of its ASPIRe strategy, a five-point plan to address liquidity fragmentation, regulatory arbitrage, and volatility while expanding regulated product offerings.

The policy also aims to position Hong Kong as a safer, more structured alternative to other Asian crypto hubs, notably Singapore, which has imposed tighter limits on retail trading.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year’s FDA approvals include Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. ABVC BioPharma (NASDAQ:ABVC)

Year-to-date gain: 405.95 percent
Market cap: US$50.61 million
Share price: US$2.98

ABVC BioPharma is a clinical-stage biopharma firm building a pipeline of products targeting a broad range of indications in ophthalmology, oncology, hematology and central nervous system (CNS) disorders.

It is advancing on six drugs and one medical device. ABVC in-licenses biotechnologies from research institutions such as Stanford University, the University of California at San Francisco and Cedars-Sinai Medical Center.

In mid-April, ABVC reported its 2024 financial results, highlighting total revenues of US$509,589 in 2024, representing 234 percent growth year-on-year. The company attributed this increase to milestone payments collected from its global licensing partners in the CNS, oncology and ophthalmology therapeutic areas.

This positive news provided a good base of support for ABVC’s share price, which started the year out at US$0.64, but by the end of April had pushed through the US$1 level.

Developments later in the summer gave the stock a further boost to the upside. On June 6, ABVC announced that its affiliate OncoX BioPharma is set to acquire the Lycopenoid Lycogen platform, including patented manufacturing technology and commercialization rights, from Asia-Pacific Biotech Developing.

‘OncoX’s acquisition of the Lycogen platform further enhances ABVC Group’s position in botanical oncology innovation,’ said ABVC CEO Dr. Uttam Patil in a press release at the time. ‘This transaction strengthens our pipeline and demonstrates our ability to convert platform assets into monetizable growth.’

In July, ABVC received a US$150,000 cash licensing payment from AiBtl BioPharma, one of its strategic partners. It represents a key milestone toward the company’s commercialization of its drug candidates ABV-1504 and ABV-1505, which are now under late-stage development for major depressive disorder and ADHD, respectively. Both of these drug candidates have active investigational new drug designations from the FDA.

That same month, the company received a US$100,000 milestone licensing payment from its licensing partner ForSeeCon Eye, which is working to develop and commercialize drugs for ophthalmic indications. This brought its cumulative licensing revenue across its strategic partnerships with AiBtl, OncoX and ForSeeCon to US$946,000.

Shares of ABVC reached a year-to-date high of US$4.74 on July 8.

2. I-Mab (NASDAQ:IMAB)

Year-to-date gain: 282.35 percent
Market cap: US$231.3 million
Share price: US$3.37

I-Mab is a global biotech firm developing precision immuno-oncology agents for the treatment of cancer.

The company’s lead candidate in its drug pipeline is givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers. Givastomig has the potential to treat other solid tumors.

I-Mab traded below US$1 for much of the year before getting a boost in Q3 from positive news flow.

On June 26, the company announced positive data from a Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. This included a strong objective response rate and favorable safety profile. A few days later, it shared the publication of the first-in-human monotherapy data for givastomig in Clinical Cancer Research, a journal of the American Association for Cancer Research.

On July 17, I-Mab signed a definitive agreement to acquire 100 percent ownership of Bridge Health Biotech. This will give I-Mab the rights to bi-specific and multi-specific applications based on the Claudin 18.2 parental antibody used in givastomig. I-Mab expects to present a topline readout of its Phase 1b dose expansion in Q1 2026.

Shares of I-Mab hit a year-to-date high of US$3.37 on August 5.

3. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 180.92 percent
Market cap: US$232.91 million
Share price: US$3.68

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein.

Belapectin has been granted fast-track designation by FDA. Galectin’s lead development program, the NAVIGATE Phase 2b/3 trial, is evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension.

In May, the company presented positive topline data from the study at the European Association for the Study of the Liver 2025 Congress. Results included a significant reduction in new esophageal varices at 18 months and fewer patients experiencing worsening liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

In early July, Galectin announced a US$10 million unsecured line of credit facility with its largest individual stockholder and board chair, Richard E. Uihlein. It is expected to fund development work through June 2026.

Galectin’s share price peaked at US$3.68 on August 5.

4. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

CytomX kicked off 2025 at US$1.06, but spent much of the first two quarters on a slow slide to a year-to-date low of US$0.43 on April 7. The stock shot up to US$2.50 on May 13 after a series of announcements.

The day prior, CytomX provided its first quarter business update, which included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer.

The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. CytomX’s goal is to initiate a Phase 2 study in advanced colorectal cancer in the first half of 2026.

At the same time, the company closed on a US$100 million underwritten offering of common stock.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) KEYTRUDA (pembrolizumab) in patients with metastatic melanoma.

Shares of CytomX hit a year-to-date high of US$2.99 on June 12.

5. Gossamer Bio (NASDAQ:GOSS)

Year-to-date gain: 129.21 percent
Market cap: US$475.2 million
Share price: US$2.16

Gossamer Bio is focused on the development and commercialization of therapies to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The clinical-stage biopharma company’s lead drug candidate, seralutinib, is currently being evaluated in a Phase 3 clinical trial for the treatment of pulmonary arterial hypertension.

Gossamer Bio’s stock value received a bump from US$1.30 to US$1.45 on March 14.

The day prior, the company shared a business update, including news that a topline data readout for its Phase 3 study of seralutinib in pulmonary arterial hypertension was on track for the fourth quarter of 2025.

On June 16, Gossamer Bio announced it had completed enrollment for an ongoing Phase 3 study on pulmonary arterial hypertension, with topline data expected out in February 2026.

On August 5, the company reported that it expects to activate the first clinical sites for a global registrational Phase 3 study on pulmonary hypertension associated with interstitial lung disease patients in Q4 2025.

Shares of Gossamer Bio hit a year-to-date high of US2.16 on August 5.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Brien Lundin, editor of Gold Newsletter, shares his thoughts on gold and silver prices, as well as what types of stocks he’s focusing on in these sectors.

In his view, the precious metals are set up for a new era.

Click here to sign up for the New Orleans Investment Conference, hosted by Lundin.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; ‘ BRW ‘ or the ‘ Company ‘) is pleased to announce the consolidation of its ownership covering a group of eight mining claims at the Mirage project pursuant to a purchase and sale agreement dated August 15, 2025, with General Partnership Osisko Baie James (‘Osisko Baie James’). Brunswick Exploration now owns 100% of the mining claims across the Mirage project.

To acquire such rights, Brunswick has agreed to renounce to its option to acquire a 90% undivided interest in the Plex property, pursuant to the third amendment to option agreement, dated August 15 2025, between Brunswick and Osisko Baie James.

In partial consideration for the termination of the Plex Property Option pursuant to this Third Amendment Agreement, Osisko Baie James shall pay to Brunswick Exploration an amount of $1,000,000 to be paid within thirty (30) days of the first publication of a technical report prepared in accordance with the requirements of Regulation 43-101 presenting a minimum of 1M oz in gold in Measure, Indicated and/or Inferred resources (as those terms are defined in National Instrument 43-101).

Grant of DSU

The Corporation announces that it has granted 821,425 deferred share units (‘DSUs’) to its non-executive directors, in accordance with the Corporation’s Deferred Share Unit Plan, available on SEDAR+ at www.sedarplus.ca. in lieu of their board fees. The DSUs were granted at a fair market value of $0.14 per DSU and will vest one year from the grant date.

About Brunswick Exploration

Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing its extensive grassroots lithium property portfolio in Canada and Greenland.

Investor Relations/information

Mr. Killian Charles, President and CEO ( info@BRWexplo.com )

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

Westport Fuel Systems Inc. (‘Westport’) (TSX: WPRT Nasdaq: WPRT) announces it has filed a preliminary short form base shelf prospectus (once filed in final form and received by the relevant Canadian securities regulatory authorities, the ‘Shelf Prospectus’) with the securities commissions in each of the provinces and territories of Canada, to replace its prior base shelf prospectus that expired on June 18, 2025.

The Shelf Prospectus, when made final, will allow Westport to offer up to USD$100,000,000 of common shares, preferred shares, subscription receipts, warrants, debt securities, or units, or any combination thereof (collectively, the ‘Securities’) during the 25-month period that the Shelf Prospectus will be effective. The Shelf Prospectus will enable Westport to access new capital or issue securities in connection with strategic acquisitions if and when needed. The amount and timing of any future offerings or issuances will be based on the Company’s financial requirements and market conditions at that time.

Westport has also filed a corresponding shelf registration statement relating to the Securities with the United States Securities and Exchange Commission (‘SEC’) on Form F-3 (the ‘Registration Statement’).

The specific terms of any future offering or issuance under the Shelf Prospectus and Registration Statement will be established at the time of such offering. There are currently no offerings or issuances planned under these filings. At the time any of the Securities covered by these filings are offered for sale, a prospectus supplement containing specific information about the terms of such offering will be filed with applicable Canadian securities regulatory authorities and the SEC.

The Registration Statement has been filed with the SEC but has not yet become effective. The Securities may not be sold, nor may offers to buy be accepted, prior to the issuance of a receipt for the final Shelf Prospectus and the time the Registration Statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

A copy of the preliminary short form base shelf prospectus can be found on SEDAR+ at www.sedarplus.ca and a copy of the corresponding shelf registration statement is available on EDGAR at www.sec.gov.

About Westport Fuel Systems

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

Our proven technologies support a wide range of clean fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals—without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

Westport Fuel Systems is headquartered in Vancouver, Canada. For more information, visit www.westport.com .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws in Canada and forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended (collectively referred to as, ‘forward-looking statements’) that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as ‘may’, ‘would’, ‘could’, ‘will’, ‘intend’, ‘plan’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘project’ and similar expressions, as they relate to us or our management. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the offer or issuance of securities.

We refer potential investors to the ‘Risk Factors’ section of our annual information form dated March 31, 2025 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated March 31, 2025 under Westport’s public filings for additional risks regarding the conduct of our business and Westport. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Investor Inquiries:
Investor Relations
T: +1 604-718-2046
E: invest@Westport.com

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com